Structure Therapeutics Reports Q3 Financial Results and Clinical Updates
Structure Therapeutics (GPCR) reported a net loss of $144.8 million for the third quarter. Despite the loss, the company maintains a strong liquidity position with $1.2 billion in cash, cash equivalents, and short-term investments as of September 30, 2026. Management expects this capital to fund operations and key clinical milestones through 2028. The report includes updates on the company's oral small molecule Amylin and GLP-1 programs aimed at chronic weight management. While providing positive clinical data updates, the stock faced downward pressure following recent trial data regarding its lead obesity drug candidates.
Tickers: $GPCR
Topics: Cash Runway Clinical Trial Data Quarterly Earnings Weight Management